#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pustular psoriasis Sickle cell anaemia Allogenic stem cell transplantation Basal cell naevus syndrome Stress cardiomyopathy Extranodal marginal zone B-cell lymphoma (MALT type) Myelodysplastic syndrome Squamous cell carcinoma of the oral cavity Philadelphia chromosome positive Hypertriglyceridaemia Neurodevelopmental disorder Infantile spasms Soft tissue necrosis Ehlers-Danlos syndrome Ocular myasthenia More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma recurrent – Diagnostics Mitochondrial myopathy – Life with Disease Leiomyosarcoma – Trials in Disease Medulloblastoma – Life with Disease Behcet’s syndrome – Basic Information Hepatic angiosarcoma – Basic Information Chondrosarcoma metastatic – Treatment Haemophilia B without inhibitors – Diagnostics Ehlers-Danlos syndrome – Treatment Mucopolysaccharidosis III – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Water For Injection Phenol, Liquefied Savolitinib Elexacaftor Maridebart Cafraglutide Tryptophan Riociguat Copper (64Cu) Chloride Specific Nucleic Acid Sna-Her2 Capivasertib Sar441566 Desflurane Lacosamide Ucp2 2-DEOXY-D-GLUCOSE Gad20-209-Fsp-A3 Protrans Rilvegostomig Somapacitan Urapidil More therapies…

    Learn about Your Condition

    Cardiovascular disorder Cardiac ventricular thrombosis Cerebrovascular accident Friedreich's ataxia Naevus flammeus Acoustic neuroma Femur fracture Turner's syndrome Hypereosinophilic syndrome Lymphocyte adoptive therapy Cholestatic pruritus Bile acid synthesis disorder Cystic fibrosis Hyperglycaemia Autoimmune uveitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Duchenne muscular dystrophy

  • Study of SGT-003 Gene Therapy for Safety and Tolerability in Walking Males with Duchenne Muscular Dystrophy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • SGT-003
    Italy

  • Long-Term Safety and Efficacy Study of Givinostat for Patients with Duchenne Muscular Dystrophy Previously Treated with Givinostat

    Recruiting

    3 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Givinostat
    Belgium France Germany Italy The Netherlands Spain

  • Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

    Recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Givinostat
    Belgium Italy The Netherlands

  • Long-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001

    Recruiting

    3 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Delandistrogene Moxeparvovec
    Belgium Germany Italy Spain

  • Efficacy and Safety of Givinostat for Non-Ambulant Patients with Duchenne Muscular Dystrophy

    Recruiting

    3 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Givinostat
    Belgium Czechia France Germany Italy The Netherlands +3

  • Study on the Safety and Effects of SQY51 for Children and Adults with Duchenne Muscular Dystrophy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Sqy51
    France
Previous Page
1 2 3 4 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!